v3.25.2
Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Revenues $ 31,660   $ 8,654   $ 45,724 $ 16,556
Cost of revenues (55)   1,407   600 2,676
Restructuring 230   0   (283) 597
Net loss (49,652) $ (62,214) (102,854) $ (108,483) (111,866) (211,337)
Corporate and Reconciling Items [Member]            
Segment Reporting Information [Line Items]            
Revenues 31,660   8,654   45,724 16,556
Cost of revenues (55)   1,407   600 2,676
Non-program expenses 24,299   22,933   43,556 45,065
People and staff augmentation 34,162   45,760   72,013 91,670
Restructuring (230)   0   283 (597)
Other segment items 4,416   8,723   6,104 13,227
Net loss (49,652)   (102,854)   (111,866) (211,337)
Corporate and Reconciling Items [Member] | zuranolone (ZURZUVAE) [Member]            
Segment Reporting Information [Line Items]            
Total program expenses 15,835   4,695   27,845 9,952
Corporate and Reconciling Items [Member] | SAGE-319 [Member]            
Segment Reporting Information [Line Items]            
Total program expenses 2,954   2,306   4,621 3,259
Corporate and Reconciling Items [Member] | SAGE-324 [Member]            
Segment Reporting Information [Line Items]            
Total program expenses (1,597)   2,286   (2,435) 6,118
Corporate and Reconciling Items [Member] | Dalzanemdor [Member]            
Segment Reporting Information [Line Items]            
Total program expenses (1,944)   15,331   (1,974) 38,999
Corporate and Reconciling Items [Member] | Other research and development programs [Member]            
Segment Reporting Information [Line Items]            
Total program expenses $ 3,472   $ 8,067   $ 6,977 $ 17,524